SPY002-072 / Spyre Therap - LARVOL DELTA

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update (PRNewswire) - "In January 2025, the Company announced its intent to study one of its anti-TL1A antibodies in RA, with Phase 2 trial initiation expected in mid-2025 and topline results in 2026. With class-leading potency and half-life established in preclinical studies, SPY002 has the potential to become the first-in-class and best-in-class anti-TL1A treatment for RA...Company announced initiation of first-in-human ('FIH') trials of both SPY002 candidates, with healthy volunteer interim data expected in the second quarter of 2025...In March 2025, the Company initiated a FIH trial of SPY003, with healthy volunteer interim data expected in the second half of 2025....The Company expects to initiate a Phase 2 clinical trial in 2025 that is intended to include each of its rational combinations, as well as all three of its lead monotherapy programs."

Clinical data • New P2 trial • Immunology • Inflammatory Bowel Disease • Rheumatoid Arthritis